Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Roche, Schering Look To Grow Hepatitis Market; Pegasys Share Surges

Executive Summary

Roche and Schering-Plough are attempting to drive sales of their hepatitis products by growing the market while increasing share

You may also be interested in...



Pegasys Market Position Secure, Roche Says; Dismisses PEG-Intron Data

Roche expects to have firmly established its leadership position in the hepatitis C market with Pegasys by the time Schering-Plough publishes the results from its ongoing head-to-head study versus PEG-Intron

Pegasys Market Position Secure, Roche Says; Dismisses PEG-Intron Data

Roche expects to have firmly established its leadership position in the hepatitis C market with Pegasys by the time Schering-Plough publishes the results from its ongoing head-to-head study versus PEG-Intron

CVS Closing 200-225 Eckerd Stores – Fewer Than Expected, Retailer Says

CVS expects to close approximately 17% of the Eckerd stores it is acquiring

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS043834

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel